Multiple neurophysiologic biomarkers evaluated the pulmonary function of ALS.

Multiple neurophysiologic biomarkers evaluated the pulmonary function of ALS. - Multiple neurophysiologic biomarkers evaluated the pulmonary function of ALS.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042222

Enrollment

Registered

2020-10-23

Start date

2020-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis(ALS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with definite, or probable and possible ALS based on the modified El Escorial criteria.

Exclusion criteria

Exclusion criteria: 1.Patients who received unapproved drugs in Japan for ALS or underwent surgery within 12 months (48 weeks) before informed consent 2.Patients with dimentia(MMSE<10) 3.Patients with severe phychiatric disorder 4.Patients who are not able to answer questionnaires 5.Patients with suicidal ideation 6.Patients undergoing treatment for respiratory disease 7.Patients with severe heart failure 8.Patients with pregnancy 9.Patients judged to be inappropriate for this study by the investigator or coordinator

Design outcomes

Primary

Measure	Time frame
The relationships between neurophysiological biomarkers (amplitude of diaphragmatic compound muscle action potential, diaphragm thickness measured by ultrasonography, thoracic excursion),%FVC of respiratory function test, PaCO2 of blood gas analysis.	—

Countries

Japan

Contacts

Public ContactNaohiko Iguchi

Nara Medical University Department of Neurology

naohiko-iguchi@naramed-u.ac.jp0744223051

Outcome results